Two Sigma Investments LP Buys 331,417 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)

Two Sigma Investments LP lifted its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 78.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 751,894 shares of the company's stock after acquiring an additional 331,417 shares during the period. Two Sigma Investments LP owned 1.54% of Cabaletta Bio worth $1,707,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Miller Financial Services LLC acquired a new position in shares of Cabaletta Bio during the 4th quarter valued at $33,000. Intech Investment Management LLC raised its holdings in Cabaletta Bio by 42.2% during the fourth quarter. Intech Investment Management LLC now owns 20,203 shares of the company's stock worth $46,000 after buying an additional 5,999 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in Cabaletta Bio during the fourth quarter worth $47,000. Wells Fargo & Company MN raised its holdings in Cabaletta Bio by 67.3% during the fourth quarter. Wells Fargo & Company MN now owns 40,412 shares of the company's stock worth $92,000 after buying an additional 16,250 shares during the last quarter. Finally, Stifel Financial Corp acquired a new position in Cabaletta Bio during the fourth quarter worth $94,000.

Analyst Ratings Changes

CABA has been the topic of several research reports. Citigroup lowered their price objective on shares of Cabaletta Bio from $17.00 to $13.00 and set a "buy" rating on the stock in a report on Friday, May 16th. UBS Group lowered their price objective on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Wells Fargo & Company lowered their price objective on shares of Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 1st. Morgan Stanley lowered their price objective on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating on the stock in a report on Tuesday, April 1st. Finally, Guggenheim upped their price objective on shares of Cabaletta Bio from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $20.33.

Cabaletta Bio Price Performance

Shares of NASDAQ CABA traded up $0.03 during trading on Wednesday, hitting $2.21. The stock had a trading volume of 2,091,247 shares, compared to its average volume of 1,359,659. Cabaletta Bio, Inc. has a 12 month low of $0.99 and a 12 month high of $13.50. The company has a market capitalization of $112.14 million, a PE ratio of -1.03 and a beta of 2.81. The firm has a fifty day moving average of $1.40 and a two-hundred day moving average of $2.03.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 21st. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.04). On average, equities analysts expect that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current fiscal year.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.